- Home
- PHAR vs SWIM Comparison
PHAR vs SWIM Comparison
Compare PHAR & SWIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- SWIM
- Stock Information
- Founded
- PHAR 1988
- SWIM 1956
- Country
- PHAR Netherlands
- SWIM United States
- Employees
- PHAR N/A
- SWIM N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- SWIM Plastic Products
- Sector
- PHAR Health Care
- SWIM Industrials
- Exchange
- PHAR Nasdaq
- SWIM Nasdaq
- Market Cap
- PHAR 731.1M
- SWIM 678.4M
- IPO Year
- PHAR N/A
- SWIM 2021
- Fundamental
- Price
- PHAR $10.00
- SWIM $6.65
- Analyst Decision
- PHAR Strong Buy
- SWIM Hold
- Analyst Count
- PHAR 3
- SWIM 4
- Target Price
- PHAR $30.00
- SWIM $6.70
- AVG Volume (30 Days)
- PHAR 3.6K
- SWIM 622.2K
- Earning Date
- PHAR 07-31-2025
- SWIM 08-05-2025
- Dividend Yield
- PHAR N/A
- SWIM N/A
- EPS Growth
- PHAR N/A
- SWIM N/A
- EPS
- PHAR N/A
- SWIM N/A
- Revenue
- PHAR $320,708,000.00
- SWIM $509,311,000.00
- Revenue This Year
- PHAR $13.31
- SWIM $9.24
- Revenue Next Year
- PHAR $7.68
- SWIM $5.86
- P/E Ratio
- PHAR N/A
- SWIM N/A
- Revenue Growth
- PHAR 24.13
- SWIM N/A
- 52 Week Low
- PHAR $6.65
- SWIM $2.75
- 52 Week High
- PHAR $12.61
- SWIM $8.41
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- SWIM 55.42
- Support Level
- PHAR $9.99
- SWIM $6.52
- Resistance Level
- PHAR $10.59
- SWIM $7.00
- Average True Range (ATR)
- PHAR 0.35
- SWIM 0.32
- MACD
- PHAR -0.14
- SWIM 0.03
- Stochastic Oscillator
- PHAR 7.45
- SWIM 65.62
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.